Neurology · AntiepilepticRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Divalproex Sodium ANDA217358 by Mankind Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:32:24 PM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated New Drug Application status for Divalproex Sodium by Mankind Pharma is significant as it enhances their competitive position in the neurology market. This approval necessitates a reassessment of market strategies for existing products in the antiepileptic segment due to increased competition. Regulatory context from FDA (FDA AP — DIVALPROEX SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing products in the same therapeutic area. The strongest clinical anchor is A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Neurology · Antiepileptic, 8 regulatory and 1 competitive items passed relevance filtering for Mankind Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Launches National Priority Voucher Program to Accelerate Drug Review Times (Humanexa Signals) — moderate corpus alignment. This approval could enhance Mankind Pharma's position in the neurology market, particularly in the antiepileptic segment, where competition is significant.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DIVALPROEX SODIUM (SUPPL) (FDA). Entity match (mankind pharma); Regulatory pathway relevance (nda). The approval status indicates a step towards final approval, which could influence compliance and market entry timelines for competitors.

Key Risks

Elevated medium regulatory exposure for Mankind Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on Mankind Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Mankind Pharma's entry into the market with Divalproex Sodium could lead to shifts in market share and pricing strategies, impacting revenue for other players in the antiepileptic space.
Upside for Mankind Pharma may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing products in the same therapeutic area.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timelines, as well as competitor responses in the antiepileptic space.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (mankind pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multimorbidity and Polypharmacy in People With HIV vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Launches National Priority Voucher Program to Accelerate Drug Review Times
Humanexa Signalsmedium relevance
Moderate corpus alignment

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
ULK1's role in cancer progression and its emerging therapeutic potential.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mankind Pharma
Divalproex Sodium

Commercial impact

medium

Mankind Pharma's entry into the market with Divalproex Sodium could lead to shifts in market share and pricing strategies, impacting revenue for other players in the antiepileptic space.

Regulatory impact

medium

The approval status indicates a step towards final approval, which could influence compliance and market entry timelines for competitors.

What to watch

Monitor for the final approval and market launch timelines, as well as competitor responses in the antiepileptic space.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.